Brandely, M.

patient f 60008 level pharmacokinetic cancer study vinorelbine triptolide grade blood 18 mg /m dose level cohort apoptosi concentration administration day 1 number toxicity therapy cycle caspase -3 activity liver activation nf-jb plasma table range liver dysfunction phase fi rst cycle journal treatment infusion subset dose levels analysis european effect cancer 4 5 bioavailability 12 mg /m caspase pharmacokinetic parameters fl ow cytometry activity parameter sample dysfunction lymphocytes lymphocyte subsets monocyte plasma concentrations liver impairment route days 1 aucinf death cohort iii response recherche pierre fabre auc 0–9 h lymphocyte pathway cytokine conversion 0.5 tumour fi gures t 1/2z cancer cells cohorts i increase 7.5 cytotoxic therapy clearance mechanism leukocyte pharmacodynamic chemotherapy